Catherine M. Engelbert - Jun 24, 2022 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: Director
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Catherine M. Engelbert
Stock symbol: RPRX
Transactions as of: Jun 24, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/24/2022, 04:59 PM
Previous filing: Mar 2, 2022
Next filing: Jan 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Award	$0	+6.33K	+33.07%	$0.00	25.5K	Jun 24, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Content

Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.